CHCC to get new COVID-19 treatment

Nov 15, 2020

The Commonwealth Healthcare Corporation will receive 10 vials of bamlanivimab, an investigational neutralizing antibody treatment for COVID-19, which received Emergency Use Authorization from the Food and Drug Administration. One vial is one treatment course. The U.S. Department of Health and Human Services plans weekly allocations of the new drug based on the need in each of the states, territories, and freely associated states. The Emergency Use Authorization allows healthcare providers to administer bamlanivimab to non-hospitalized patients with confirmed COVID-19, who are experiencing mild to moderate symptoms and are at high risk for severe symptoms and hospitalization. Congress made nearly $10 billion available through the CARES Act and other emergency funding to support the rapid development of effective medical countermeasures, like bamlanivimab, to combat the coronavirus crisis.